Intrinsiqs

Is Outlook Therapeutics, Inc. overvalued?

Outlook Therapeutics, Inc. (OTLK) — key valuation metrics and fundamentals.

No verdict
Price
$1.62
Fair value
Current P/E
Normal P/E
Market cap
$65.8M
Dividend yield
Return on equity
Sector
Healthcare

See the full interactive analysis →

Fair value compares OTLK's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 30 Jun 2026.